全文获取类型
收费全文 | 180篇 |
免费 | 8篇 |
专业分类
妇产科学 | 40篇 |
基础医学 | 16篇 |
口腔科学 | 2篇 |
临床医学 | 9篇 |
内科学 | 28篇 |
皮肤病学 | 1篇 |
神经病学 | 2篇 |
特种医学 | 11篇 |
外科学 | 39篇 |
预防医学 | 9篇 |
药学 | 8篇 |
肿瘤学 | 23篇 |
出版年
2023年 | 1篇 |
2022年 | 1篇 |
2021年 | 4篇 |
2020年 | 2篇 |
2019年 | 2篇 |
2018年 | 3篇 |
2017年 | 2篇 |
2016年 | 3篇 |
2015年 | 3篇 |
2014年 | 9篇 |
2013年 | 8篇 |
2012年 | 11篇 |
2011年 | 10篇 |
2010年 | 3篇 |
2009年 | 5篇 |
2008年 | 13篇 |
2007年 | 11篇 |
2006年 | 14篇 |
2005年 | 8篇 |
2004年 | 5篇 |
2003年 | 9篇 |
2002年 | 4篇 |
2001年 | 3篇 |
2000年 | 4篇 |
1999年 | 3篇 |
1998年 | 1篇 |
1992年 | 2篇 |
1991年 | 7篇 |
1990年 | 1篇 |
1989年 | 4篇 |
1987年 | 1篇 |
1984年 | 1篇 |
1983年 | 1篇 |
1978年 | 2篇 |
1975年 | 2篇 |
1973年 | 3篇 |
1972年 | 2篇 |
1971年 | 1篇 |
1969年 | 1篇 |
1968年 | 4篇 |
1967年 | 1篇 |
1966年 | 2篇 |
1965年 | 2篇 |
1964年 | 1篇 |
1963年 | 1篇 |
1962年 | 2篇 |
1961年 | 2篇 |
1957年 | 1篇 |
1954年 | 1篇 |
1940年 | 1篇 |
排序方式: 共有188条查询结果,搜索用时 15 毫秒
1.
Lorente Nicolas Sherriff Nigel Panochenko Oksana Marcus Ulrich Dutarte Maria Kuske Matthias Aussó Susanna Huber Jörg Krone Michael Schink Susanne Barbara Cawley Caoimhe Casabona Jordi Folch Cinta 《Journal of community health》2021,46(3):545-556
Journal of Community Health - Little is known about Community Health Workers (CHWs) who work in non-clinical settings to provide sexual health support around HIV, viral hepatitis, and other... 相似文献
2.
Thomas Elter Peter Borchmann Holger Schulz Marcel Reiser Sven Trelle Roland Schnell Markus Jensen Peter Staib Timo Schink?the Hartmut Stützer Jürgen Rech Martin Gramatzki Walter Aulitzky Ibrahim Hasan Andreas Josting Michael Hallek Andreas Engert 《Journal of clinical oncology》2005,23(28):7024-7031
PURPOSE: To determine the efficacy and safety of a newly developed concomitant administration of fludarabine and alemtuzumab (FluCam) in patients with relapsed or refractory B-cell chronic lymphocytic leukemia (B-CLL). PATIENTS AND METHODS: A total of 36 patients were treated in this phase II study (median age, 61.47 years; mean number of prior chemotherapies, 2.6; Binet stage C, n = 28). After an initial dose escalation of alemtuzumab over 3 days, alemtuzumab 30 mg and fludarabine 30 mg/m2 were administered on 3 consecutive days. Treatment was repeated after 28 days for up to six cycles. Restaging (following National Cancer Institute criteria) was carried out after cycles 2 and 4 and 1 month after the end of treatment. RESULTS: The overall response rate was 83% (11 complete responses, 19 partial responses, one stable disease, and five progressive diseases). Two patients with progressive disease developed fungal pneumonias, and one patient died as a result of Escherichia coli sepsis. Two subclinical cytomegalovirus reactivations occurred. CONCLUSION: The new FluCam regimen is effective and feasible in patients with relapsed and refractory B-CLL. 相似文献
3.
Thorsten Suess Cornelius Remschmidt Susanne B Schink Brunhilde Schweiger Andreas Nitsche Kati Schroeder Joerg Doellinger Jeanette Milde Walter Haas Irina Koehler Gérard Krause Udo Buchholz 《BMC infectious diseases》2012,12(1):1-16
Background
Previous controlled studies on the effect of non-pharmaceutical interventions (NPI) - namely the use of facemasks and intensified hand hygiene - in preventing household transmission of influenza have not produced definitive results. We aimed to investigate efficacy, acceptability, and tolerability of NPI in households with influenza index patients.Methods
We conducted a cluster randomized controlled trial during the pandemic season 2009/10 and the ensuing influenza season 2010/11. We included households with an influenza positive index case in the absence of further respiratory illness within the preceding 14 days. Study arms were wearing a facemask and practicing intensified hand hygiene (MH group), wearing facemasks only (M group) and none of the two (control group). Main outcome measure was laboratory confirmed influenza infection in a household contact. We used daily questionnaires to examine adherence and tolerability of the interventions.Results
We recruited 84 households (30 control, 26 M and 28 MH households) with 82, 69 and 67 household contacts, respectively. In 2009/10 all 41 index cases had a influenza A (H1N1) pdm09 infection, in 2010/11 24 had an A (H1N1) pdm09 and 20 had a B infection. The total secondary attack rate was 16% (35/218). In intention-to-treat analysis there was no statistically significant effect of the M and MH interventions on secondary infections. When analysing only households where intervention was implemented within 36 h after symptom onset of the index case, secondary infection in the pooled M and MH groups was significantly lower compared to the control group (adjusted odds ratio 0.16, 95% CI, 0.03-0.92). In a per-protocol analysis odds ratios were significantly reduced among participants of the M group (adjusted odds ratio, 0.30, 95% CI, 0.10-0.94). With the exception of MH index cases in 2010/11 adherence was good for adults and children, contacts and index cases.Conclusions
Results suggest that household transmission of influenza can be reduced by the use of NPI, such as facemasks and intensified hand hygiene, when implemented early and used diligently. Concerns about acceptability and tolerability of the interventions should not be a reason against their recommendation.Trial registration
The study was registered with ClinicalTrials.gov (Identifier NCT00833885). 相似文献4.
Wentzell Nadine Haug Ulrike Schink Tania Engel Susanne Liebentraut Judith Linder Roland Onken Marlies Schaefer Christof Dathe Katarina 《Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz》2018,61(8):1022-1029
Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz - Aufgrund des teratogenen Potenzials von Valproat wurden die Empfehlungen zur Risikoaufklärung und Verordnung bei... 相似文献
5.
6.
7.
Kushner DM Connor JP Sanchez F Volk M Schink JC Bailey HH Harris LS Stewart SL Fine J Hartenbach EM;Wisconsin Oncology Network 《Gynecologic oncology》2007,105(2):358-364
OBJECTIVE: Results of the ICON4/AGO-OVAR-2.2 trial suggest that a platinum/taxane combination provides a survival benefit in relapsed, platinum-sensitive ovarian cancer compared to platinum alone. The optimal specific combination has yet to be determined. The current study evaluates weekly docetaxel and carboplatin in this setting. METHODS: Using a prospective phase II design, patients received weekly docetaxel (35 mg/m2) and carboplatin (AUC=2) administered days 1, 8, and 15 of a 28-day cycle. Initial treatment with a platinum-based regimen was required, with a treatment-free interval of at least 3 months. Patients could have received one prior regimen for recurrence. Biologically evaluable disease (CA-125) could be followed only if measurable disease was not present. Quality of life analysis utilized the FACT-O and FACT/GOG-Ntx scales. RESULTS: Thirty-six patients enrolled in the trial over 29 months. The majority had ovarian cancer (89%) and stage III/IV (97%) disease, with a median initial disease-free interval of 12 months. Most subjects were treated for first recurrence (81%) and had measurable disease (58%). The overall response rate was 67% (PR=52%, CR=15%), with 22% stable disease. Grade 3/4 neutropenia was common (48%) while serious anemia and thrombocytopenia were not. Neuropathy was generally mild and manageable. Carboplatin hypersensitivity led to 11 subjects coming off trial (31%). Diphenhydramine premedication produced a nonsignificant decrease in reaction rate. There was no detectable difference in quality of life due to therapy. CONCLUSION: The weekly regimen of carboplatin and docetaxel has a good response rate with an acceptable toxicity profile. 相似文献
8.
9.
Schink JC Weller E Harris LS Cella D Gerstner J Falkson C Wadler S 《Cancer journal (Sudbury, Mass.)》2001,7(2):155-164
10.
Kathleen Collier Cordula Schink Anna Mary Young Katharine How Michael Seckl Philip Savage 《Journal of oncology pharmacy practice》2008,14(1):51-55
OBJECTIVE: To review the experience of treatment with etoposide phosphate in patients with acute etoposide hypersensitivity treated in a large tertiary referral center hospital specializing in curable malignancies. CASE SUMMARIES: The cases of 6 patients with advanced malignancies who experienced acute etoposide hypersensitivity are documented. There were 3 male and 3 female patients and their ages ranged from 16 to 68. Four patients had curable malignancies with trophoblast tumors or germ cell tumors and two were receiving palliative chemotherapy for other malignancies. All of the 6 patients who experienced etoposide hypersensitivity developed their symptoms in the first few minutes of the initial infusion. The most common symptoms were chest pain, facial flushing, and bronchospasm. All of the patients had emergency treatment with discontinuation of the infusion and usually the administration of hydrocortisone and chlorpheniramine, which lead to the rapid resolution of their symptoms.For the next cycle of chemotherapy each patient was rechallenged with etoposide phosphate, with steroid cover given in only two of the cases. None of the 6 patients experienced any hypersensitivity symptoms on treatment with etoposide phosphate and in one the steroids were withdrawn for all the subsequent cycles. The 4 patients with curable malignancies all remain disease free, while the 2 palliative patients obtained significant control of their disease. DISCUSSION: Etoposide is one of the most important chemotherapy drugs in the treatment of many curable malignancies but an acute hypersensitivity reaction occurs in around 1% of patients. Retreatment with etoposide in these patients is difficult and generally alternative drugs/regimens have to be used. A small number of case reports have suggested that etoposide phosphate can be safely used in these patients and 6 cases have been found in the pharmacy records where this has been done. In all of the patients, treatment with etoposide phosphate proceeded without any symptoms or the use of repeated steroid cover in 5 of the 6 patients. CONCLUSION: Etoposide hypersensitivity is a rare clinical problem and responds promptly to drug discontinuation, steroids, and chlorpheniramine. Patients with previous etoposide hypersensitivity can safely be treated with etoposide phosphate and do not need any additional hypersensitivity prophylaxis. 相似文献